NHU(SZ:002001)2024-04-22 14:38Financial Performance - The estimated net profit attributable to shareholders for Q1 2024 is projected to be between 836.11 million and 900.42 million CNY, representing a year-on-year growth of 30% to 40% compared to 643.16 million CNY in the same period last year[2]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 820.99 million and 879.63 million CNY, indicating a year-on-year increase of 40% to 50% from 586.42 million CNY[2]. - The basic earnings per share is forecasted to be between 0.27 CNY and 0.29 CNY, up from 0.21 CNY in the previous year[2]. Strategic Development - The company aims to expand market share through coordinated production and sales efforts, focusing on products like methionine and vitamins, which have seen increased sales volume compared to last year[3]. - Future strategies include a commitment to integrated, series, and collaborative development, emphasizing "Chemical +" and "Biological +" strategic pathways[3]. - The company plans to enhance its application research and service capabilities, focusing on functional chemicals in nutrition, flavors, high-performance new materials, and active pharmaceutical ingredients[4]. - The establishment of modern production bases in regions such as Zhejiang and Shandong is intended to extend the industrial chain and deepen the global marketing network[4]. - The company is actively monitoring and nurturing opportunities in strategic emerging industries, including plant protection, new energy, energy conservation, and environmental protection[4]. Investment Caution - The financial data in the earnings forecast has not been audited by registered accountants, and investors are advised to be cautious regarding investment risks[5].